1. Home
  2. DMRC vs MOLN Comparison

DMRC vs MOLN Comparison

Compare DMRC & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digimarc Corporation

DMRC

Digimarc Corporation

HOLD

Current Price

$9.48

Market Cap

170.6M

Sector

Technology

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$3.82

Market Cap

143.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMRC
MOLN
Founded
2008
2004
Country
United States
Switzerland
Employees
N/A
134
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
170.6M
143.3M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
DMRC
MOLN
Price
$9.48
$3.82
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$10.00
$8.38
AVG Volume (30 Days)
276.6K
3.6K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
18.58
N/A
EPS
N/A
N/A
Revenue
$25,213,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$374.07
P/E Ratio
N/A
N/A
Revenue Growth
15.69
N/A
52 Week Low
$4.07
$3.41
52 Week High
$17.47
$5.36

Technical Indicators

Market Signals
Indicator
DMRC
MOLN
Relative Strength Index (RSI) 38.41 45.21
Support Level $9.52 $3.61
Resistance Level $10.31 $3.96
Average True Range (ATR) 1.26 0.13
MACD -0.68 0.00
Stochastic Oscillator 3.78 33.33

Price Performance

Historical Comparison
DMRC
MOLN

About DMRC Digimarc Corporation

Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: